PEAK6 Investments’s NovoCure NVCR Stock Holding History

PEAK6 Investments’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,500	Closed	-$128K	–	3915
2024 Q2	$128K	Hold	7,500	–	–	﹤0.01%	2941
2024 Q1	$117K	Buy	+7,500	New	+$110K	﹤0.01%	3315
2023 Q2	–	Sell	-35,300	Closed	-$2.12M	–	4451
2023 Q1	$2.12M	Buy	+35,300	New	+$2.82M	0.01%	1263
2021 Q1	–	Sell	-109,600	Closed	-$19M	–	5333
2020 Q4	$19M	Sell	109,600 -98,200	-47%	-$13.4M	0.04%	420
2020 Q3	$23.1M	Buy	207,800 +197,900	+1,999%	+$15.8M	0.06%	291
2020 Q2	$587K	Buy	9,900 +4,900	+98%	+$322K	﹤0.01%	2532
2020 Q1	$337K	Buy	+5,000	New	+$395K	﹤0.01%	2399
2019 Q4	–	Sell	-5,900	Closed	-$441K	–	3840
2019 Q3	$441K	Buy	+5,900	New	+$472K	﹤0.01%	2364
2018 Q4	–	Sell	-22,200	Closed	-$1.16M	–	4456
2018 Q3	$1.16M	Buy	+22,200	New	+$884K	0.01%	1865

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PEAK6 Investments's NVCR Position: Q3 2024 in Review

PEAK6 Investments sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 11,107 shares — an estimated $190K sold.

PEAK6 Investments first reported a position in NVCR in Q4 2019 and held it in 8 quarters. The position peaked at $2.19M in Q2 2020. 225 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

PEAK6 Investments reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
PEAK6 Investments sold 11,107 NovoCure shares in Q3 2024, an estimated $190K.
PEAK6 Investments first reported a position in NovoCure in Q4 2019 and held it in 8 quarters.
PEAK6 Investments's NovoCure position peaked at $2.19M in Q2 2020.
225 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.